Tigecycline Immunodetection Using Developed Group-Specific and Selective Antibodies for Drug Monitoring Purposes
Rattachement africain : ru. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Tigecycline (TGC), a third-generation tetracycline, is characterized by a more potent and broad antibacterial activity, and the ability to overcome different mechanisms of tetracycline resistance. TGC has proven to be of value in treatment of multidrug-resistant infections, but therapy can be complicated by multiple dangerous side effects, including direct drug toxicity. Given that, a TGC immunodetection method has been developed for therapeutic drug monitoring to improve the safety and efficacy of therapy. The developed indirect competitive ELISA utilized TGC selective antibodies and group-specific antibodies interacting with selected coating TGC conjugates. Both assay systems showed high sensitivity (IC50) of 0.23 and 1.59 ng/mL, and LOD of 0.02 and 0.05 ng/mL, respectively. Satisfactory TGC recovery from the spiked blood serum of healthy volunteers was obtained in both assays and laid in the range of 81–102%. TGC concentrations measured in sera from COVID-19 patients with secondary bacterial infections were mutually confirmed by ELISA based on the other antibody–antigen interaction and showed good agreement (R2 = 0.966). A TGC pharmacokinetic (PK) study conducted in three critically ill patients proved the suitability of the test to analyze the therapeutic concentrations of TGC. Significant inter-individual PK variability revealed in this limited group supports therapeutic monitoring of TGC in individual patients and application of the test for population pharmacokinetic modelling.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Tigecycline Immunodetection Using Developed Group-Specific and Selective Antibodies for Drug Monitoring Purposes
- Date Crossref
- 04/03/2023
- Éditeur
- MDPI AG
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences pays non établi dans la noticeStructure de recherche
-
Lomonosov Moscow State University pays non établi dans la noticeUniversité ou école supérieure
-
Ministry of Health of the Russian Federation pays non établi dans la noticeOrganisme public
-
I. Mechnikov Research Institute for Vaccines and Sera pays non établi dans la noticeStructure de recherche
-
Faculty of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
Federal Center for Treatment and Rehabilitation Ministry of Health pays non établi dans la noticeOrganisme public
Research Institute of Vaccines and Sera. Mechnikov of the Russian Academy of Medical Sciences, Lomonosov Moscow State University et Ministry of Health of the Russian Federation, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.